Like other AAS, boldenone is an agonist of the androgen receptor (AR).[7] The activity of boldenone is mainly anabolic, with a low androgenic potency. Boldenone will increase nitrogen retention, protein synthesis, increases appetite and stimulates the release of erythropoietin in the kidneys.[8]
Ciba reportedly patented boldenone in 1949.[7] It subsequently developed several experimental esters of the drug in the 1950s and 1960s.[7] One of these was boldenone undecylenate, which was introduced for clinical use under the brand name Parenabol and saw some use in the late 1960s and early 1970s.[7] However, it was discontinued before the end of the 1970s.[7] Subsequently, boldenone undecylenate was introduced by Squibb under the brand name Equipose for veterinary use, most commonly in horses.[7]
Society and culture
Generic names
Boldenone is the generic name of the drug and its INNTooltip International Nonproprietary Name and BANTooltip British Approved Name.[3][4][5][6]
Brand names
Boldenone is marketed as veterinary drug as boldenone undecylenate (a derivative of boldenone) under the following brand names: Boldebal H, Equipoise, and Sybolin.[6] It is marketed as a veterinary combination drug with methandriol under the brand name Drive.[6]
In Ukraine, it is marketed for human consumption as the injectable steroid Boldenol.[9]
^Forbes GB (June 1985). "The effect of anabolic steroids on lean body mass: the dose response curve". Metabolism: Clinical and Experimental. 34 (6): 571–3. doi:10.1016/0026-0495(85)90196-9. PMID3999979.